SelectScience InterviewsLife Sciences

Screening of immune engager compounds using CRC patient-derived organoids (or “mini-organs”) and immune T cells subsets

9 May 2025
Screening of immune engager compounds using CRC patient-derived organoids (or “mini-organs”) and immune T cells subsets

In this presentation, Dr. Maria Pinna, Research Fellow and Tissue Culture Section Lead at the Institute of Cancer and Genomic Sciences, University of Birmingham, discusses her team's cutting-edge work using patient-derived colorectal cancer organoids (also known as mini-organs) to study immune T cell interactions and screen immune engager compounds. She provides an overview of organoid technology, tracing its development from foundational discoveries to its current applications in personalized medicine, disease modeling, and drug screening.

Tags